

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CHINA BIOTECH SERVICES HOLDINGS LIMITED**

**中國生物科技服務控股有限公司**

*(Incorporated in the Cayman Islands and continued in Bermuda with limited liability)*

**(Stock code: 8037)**

### **VOLUNTARY ANNOUNCEMENT MEMORANDUM OF UNDERSTANDING SIGNED WITH THE HONG KONG-SHENZHEN INNOVATION AND TECHNOLOGY PARK LIMITED**

This announcement is made by China Biotech Services Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to keep shareholders of the Company (the “**Shareholders**”) and potential investors informed of the latest business development of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 18 April 2024, The Hong Kong-Shenzhen Innovation and Technology Park Limited (“**HSITPL**”) convened the HSITP Partnership Launching Ceremony following its signing of memorandum of understandings with approximately sixty partner organizations, including the Company. Pursuant to the memorandum of understanding (the “**MOU**”) entered between the Company and HSITPL (collectively the “**Parties**”), the Parties have agreed, among other things, to collaborate on the development of the Hong Kong-Shenzhen Innovation and Technology Park (the “**Park**”) located at the Lok Ma Chau Loop in the Hetao Shenzhen-Hong Kong Innovation and Technology Cooperation Zone.

#### **THE MOU**

The principal terms of the MOU are set out below:

- Parties:
- (i) The Company; and
  - (ii) The Hong Kong-Shenzhen Innovation and Technology Park Limited.

Subject matters: Pursuant to the MOU, the Company will support the innovation and technology (“**I&T**”) venture companies in the Park to gain market access in the following manner:–

- (1) Introduce about five (5) subsidiaries and partner companies of the Company to land in the Park and to facilitate their expansion into China and overseas markets;
- (2) Establish a molecular diagnostics laboratory, a chimeric antigen receptor T cell (“**CAR-T**”) development center and a Boron Neutron Capture Therapy (“**BNCT**”) center in the Park with approximately 200 staff and provide contract research organization (“**CRO**”) services, including CAR-T cell manufacturing, research and development (“**R&D**”) for cell therapy, BNCT treatment and R&D, and other professional services at preferential prices to the Park’s community companies and to the public; and
- (3) Consider to establish other R&D centers in the Park.

On the other hand, HSITPL will support the Company’s business expansion through admitting the Company to establish a presence at the Park and expanding the Company’s network in the following manner:

- (1) Facilitate the entry of the subsidiaries and partner companies of Company to the Park through various entrepreneurship programs, and provide office tenancy and essential business operation support;
- (2) Collaborate with the Company to support the Park’s community companies in their development of I&T infrastructure in the areas of molecular diagnostics and cell therapies; and
- (3) Facilitate and provide necessary support and resources to the Company to establish R&D centers in the Park.

Term: One (1) year from the date on which the MOU is signed (the “**Term**”), unless terminated by either party by providing sixty (60) days’ written notice. The Parties may extend the Term by mutual agreement in writing.

## REASONS FOR AND BENEFITS OF ENTERING INTO THE MOU

The development of BNCT cancer treatment center and the provision of tumor immune cell therapy services are among the key business activities of the Group. The MOU signifies that first BNCT center in Hong Kong will be set up by the Company in the Park, serving late stage cancer patients in Hong Kong, the Greater Bay Area, Southeast Asia and South Asia in the future. The BNCT equipment and related services will be provided by Sumitomo Heavy Industries, Ltd (“**Sumitomo**”) and Stella Pharma Corporation (“**Stella Pharma**”) pursuant to agreements previously entered into between each party and the Group. The Company also acknowledges that each of Sumitomo and Stella Pharma has signed a memorandum of understanding with HSITPL.

The Board believes that the collaboration with HSITPL creates synergy in building an integrated center which houses the Group’s molecular diagnostics laboratory, CAR-T development center and BNCT center. Such integrated center will facilitate the production of the first CD20-targeted autologous CAR-T therapy drug and the development of BNCT in Hong Kong. The Board further believes that the entering of the MOU aligns with the government policies in fostering the development of Hong Kong into a regional hub for scientific research and promoting collaboration between the Mainland and Hong Kong.

By order of the Board  
**China Biotech Services Holdings Limited**  
**Liu Xiaolin**  
*Chairman and Executive Director*

Hong Kong, 18 April 2024

*As at the date of this announcement, the board of Directors comprises three executive Directors, namely, Mr. Liu Xiaolin (Chairman), Mr. He Xun, and Mr. Huang Song; one non-executive Director, namely, Ms. Chui Hoi Yam; and three independent non-executive Directors, namely, Mr. Yan Guoxiang, Dr. Ho Ivan Chun Kit and Mr. Qian Hongji.*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and there are no other matters the omission of which would make any statement herein or this announcement misleading.*

*This announcement will remain on the “Latest Listed Company Information” page of the website of The Stock Exchange of Hong Kong Limited at [www.hkexnews.hk](http://www.hkexnews.hk) for at least 7 days from the date of its publication and on the website of the Company at [www.cbshhk.com](http://www.cbshhk.com).*